Thiard News@F4F

@newsen.bsky.social

1 week ago

Allergan Aesthetics Unveils Groundbreaking Data on TrenibotE at 2026 AAD Meeting Allergan Aesthetics presented new findings on the safety and efficacy of TrenibotulinumtoxinE at the American Academy of Dermatology Meeting 2026, showcasing significant advancements.

Allergan Aesthetics Unveils Groundbreaking Data on TrenibotE at 2026 AAD Meeting #USA #North_Chicago #Allergan_Aesthetics #TrenibotulinumtoxinE #AAD_2026

Thiard News@F4F

@newsen.bsky.social

1 week ago

Rosalind Franklin University Receives NCI Grant for Pancreatic Cancer Research Breakthrough The National Cancer Institute has awarded a significant grant to Rosalind Franklin University to investigate pancreatic cancer cachexia.

Rosalind Franklin University Receives NCI Grant for Pancreatic Cancer Research Breakthrough #United_States #pancreatic_cancer #North_Chicago #Rosalind_Franklin #Research_Grant

Thiard News@F4F

@newsen.bsky.social

1 week ago

Allergan Aesthetics Showcases Innovative Research at AMWC 2026 on Aesthetic Treatments At the 2026 Aesthetic & Anti-Aging Medicine World Congress, Allergan Aesthetics unveils 21 evidence-based e-posters, emphasizing safety and efficacy in aesthetic treatments.

Allergan Aesthetics Showcases Innovative Research at AMWC 2026 on Aesthetic Treatments #United_States #North_Chicago #Allergan_Aesthetics #TrenibotulinumtoxinE #BOTOX®

Thiard News@F4F

@newsen.bsky.social

1 week ago

Allergan Aesthetics Introduces the Next Generation of JUVÉDERM® at AMWC Monaco in 2026 Discover the innovative shift in aesthetics as Allergan Aesthetics reveals new trends towards 'undetectable' beauty with JUVÉDERM® at AMWC 2026.

Allergan Aesthetics Introduces the Next Generation of JUVÉDERM® at AMWC Monaco in 2026 #USA #North_Chicago #Allergan_Aesthetics #JUVÉDERM® #HA_injectables

Thiard News@F4F

@newsen.bsky.social

1 week ago

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy AbbVie announces FDA approval for Venetoclax in combination with Acalabrutinib for untreated chronic lymphocytic leukemia, enhancing treatment options.

AbbVie’s Venetoclax Receives FDA Approval for CLL Combination Therapy #United_States #AbbVie #North_Chicago #CLL #venetoclax

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

AbbVie Teams Up with Major League Baseball to Combat Cancer Through Innovative Campaign AbbVie partners with MLB in a groundbreaking initiative, launching 'Striking Out Cancer' to raise awareness and funds for cancer research during the baseball season.

AbbVie Teams Up with Major League Baseball to Combat Cancer Through Innovative Campaign #USA #North_Chicago #AbbviesCancerCampaign #MLBPartnership #StandUpToCancer

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Skyrizi Shows Promising Results in Phase 3 Induction Trial for Crohn's Disease Patients AbbVie's Skyrizi (risankizumab) demonstrates significant efficacy in a Phase 3 trial for Crohn's disease patients, offering new hope for treatment.

Skyrizi Shows Promising Results in Phase 3 Induction Trial for Crohn's Disease Patients #United_States #Crohn's_Disease #North_Chicago #Skyrizi #Risankizumab

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Rosalind Franklin University Expands Helix 51 Incubator to Boost Biotech Growth Rosalind Franklin University expands its Helix 51 incubator, doubling laboratory space to support more biotech companies in Lake County, Illinois.

Rosalind Franklin University Expands Helix 51 Incubator to Boost Biotech Growth #United_States #North_Chicago #Helix_51 #Rosalind_Franklin #Biotech_Expansion

Thiard News@F4F

@newsen.bsky.social

4 weeks ago

AbbVie Reveals Positive Outcomes for ABBV-295 in Weight Management Study AbbVie has announced promising results for its weight management drug ABBV-295, showing significant reductions in body weight during a Phase 1 study. Learn more here.

AbbVie Reveals Positive Outcomes for ABBV-295 in Weight Management Study #USA #Weight_Management #AbbVie #North_Chicago #ABBV-295

Thiard News@F4F

@newsen.bsky.social

1 month ago

AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment AbbVie has submitted an application for the approval of ubadacitinib as a treatment for adults and adolescents with vitiligo, marking a potential breakthrough in autoimmune disease therapy.

AbbVie's Ubadacitinib Receives FDA and EMA Approval for Vitiligo Treatment #United_States #AbbVie #North_Chicago #Vitiligo #Ubadacitinib

Thiard News@F4F

@newsen.bsky.social

1 month ago

AbbVie Announces Major $380 Million Investment to Enhance Pharmaceutical Production in North Chicago AbbVie is set to invest $380 million in North Chicago for the construction of two new manufacturing facilities, focusing on advanced neuroscience and obesity medications.

AbbVie Announces Major $380 Million Investment to Enhance Pharmaceutical Production in North Chicago #United_States #Active_Pharmaceutical_Ingredient #AbbVie #North_Chicago

Thiard News@F4F

@newsen.bsky.social

1 month ago

FDA Greenlights VENCLEXTA® and Acalabrutinib for Frontline CLL Treatment Updated guidelines now permit the use of VENCLEXTA® and Acalabrutinib for previously untreated patients with chronic lymphocytic leukemia, offering new hope and options.

FDA Greenlights VENCLEXTA® and Acalabrutinib for Frontline CLL Treatment #USA #North_Chicago #CLL #VENCLEXTA® #Acalabrutinib

Thiard News@F4F

@newsen.bsky.social

1 month ago

Rosalind Franklin University Expands Clinical Research Capabilities with New Lease Agreement Rosalind Franklin University has signed a significant lease for clinical research expansion with CCRII, enhancing Illinois' clinical trial capacity dramatically.

Rosalind Franklin University Expands Clinical Research Capabilities with New Lease Agreement #United_States #Clinical_Trials #North_Chicago #Rosalind_Franklin_University #CCRII

Thiard News@F4F

@newsen.bsky.social

1 month ago

AbbVie Announces Quarterly Dividend as Part of Growth Strategy AbbVie Inc. has declared a quarterly cash dividend of $1.73 per share, reflecting significant growth since its inception. This dividend is payable in May, benefiting loyal shareholders.

AbbVie Announces Quarterly Dividend as Part of Growth Strategy #United_States #Dividend #AbbVie #North_Chicago #NYSE_ABBV

Thiard News@F4F

@newsen.bsky.social

2 months ago

AbbVie Shares 2025 Financial Performance: Outlook and Innovations Highlighted AbbVie reported its financial results for 2025, showcasing notable revenue growth across multiple portfolios, despite slight declines in EPS.

AbbVie Shares 2025 Financial Performance: Outlook and Innovations Highlighted #United_States #AbbVie #North_Chicago #Skyrizi #IPRD

Thiard News@F4F

@newsen.bsky.social

2 months ago

AbbVie Seeks FDA and EMA Approval for RINVOQ® in Vitiligo Treatment for All Ages AbbVie has submitted regulatory applications to the FDA and EMA for RINVOQ® targeting vitiligo in both adults and adolescents, addressing unmet medical needs.

AbbVie Seeks FDA and EMA Approval for RINVOQ® in Vitiligo Treatment for All Ages #USA #AbbVie #North_Chicago #RINVOQ #Vitiligo

Thiard News@F4F

@newsen.bsky.social

2 months ago

Rosalind Franklin University Researcher Receives $1.9M NIH Grant for Neurological Study Dr. Hongkyun Kim from Rosalind Franklin University has been awarded a $1.9 million NIH grant to study the intricacies of neurological diseases focusing on calcium channels.

Rosalind Franklin University Researcher Receives $1.9M NIH Grant for Neurological Study #United_States #NIH_Grant #North_Chicago #Rosalind_Franklin_Univ #Hongkyun_Kim

Thiard News@F4F

@newsen.bsky.social

2 months ago

AbbVie Shares Promising Phase 3 Data for Epcoritamab in DLBCL Patients AbbVie recently released encouraging topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab, targeting relapsed/refractory DLBCL patients, indicating improvements in patient outcomes.

AbbVie Shares Promising Phase 3 Data for Epcoritamab in DLBCL Patients #USA #Epcoritamab #AbbVie #North_Chicago #DLBCL

Thiard News@F4F

@newsen.bsky.social

2 months ago

AbbVie Partners with Trump Administration to Enhance Drug Access and Affordability for Americans AbbVie collaborates with the Trump administration to improve drug access and affordability for millions of Americans, pledging significant investment.

AbbVie Partners with Trump Administration to Enhance Drug Access and Affordability for Americans #USA #AbbVie #North_Chicago #TrumpRx #ALPHAGAN

Thiard News@F4F

@newsen.bsky.social

2 months ago

AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors AbbVie and RemeGen have signed an exclusive licensing deal to develop RC148, a groundbreaking bispecific antibody, targeting advanced solid tumors, enhancing cancer immunotherapy.

AbbVie and RemeGen Forge Deal for Innovative Bispecific Antibody Targeting Solid Tumors #United_States #AbbVie #North_Chicago #RemeGen #RC148

Thiard News@F4F

@newsen.bsky.social

2 months ago

UP Oncolytics Awarded Grant to Develop Innovative Cancer Therapy at RFU UP Oncolytics, a UNC company, has been awarded a $75,000 grant to advance their cancer drug development efforts targeted at glioblastoma.

UP Oncolytics Awarded Grant to Develop Innovative Cancer Therapy at RFU #United_States #Glioblastoma #North_Chicago #UP_Oncolytics #RFU

Thiard News@F4F

@newsen.bsky.social

3 months ago

Rosalind Franklin University Receives $1.7 Million NIH Funding for Autism and Schizophrenia Research Rosalind Franklin University has received a significant NIH grant to explore social recognition mechanisms in schizophrenia and autism spectrum disorders, potentially leading to new therapies.

Rosalind Franklin University Receives $1.7 Million NIH Funding for Autism and Schizophrenia Research #United_States #NIH_Grant #North_Chicago #Rosalind_Franklin #Joanna_Dabrowska

Thiard News@F4F

@newsen.bsky.social

3 months ago

Rosalind Franklin University Expands Innovation with Tolmar's New Lab in Illinois Rosalind Franklin University has welcomed Tolmar, Inc. to its Innovation and Research Park, enhancing pharmaceutical development opportunities in Illinois.

Rosalind Franklin University Expands Innovation with Tolmar's New Lab in Illinois #United_States #North_Chicago #Rosalind_Franklin #Tolmar #Pharmaceutical_Lab

Thiard News@F4F

@newsen.bsky.social

3 months ago

ECLIPSE Trial Data Highlights Atogepant's Effectiveness Over Placebo for Migraine Treatment AbbVie presents promising ECLIPSE trial results at the European Headache Congress, showcasing Atogepant's superiority over placebo for acute migraine treatment.

ECLIPSE Trial Data Highlights Atogepant's Effectiveness Over Placebo for Migraine Treatment #USA #AbbVie #North_Chicago #Migraine #Atogepant

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie's ECLIPSE Study Data Unveils Promising Migraine Treatment Options AbbVie reveals groundbreaking results from the ECLIPSE study, highlighting atogepant's significant efficacy in acute migraine treatment, aiming to enhance patient care.

AbbVie's ECLIPSE Study Data Unveils Promising Migraine Treatment Options #USA #AbbVie #North_Chicago #Eclipse #Atogepant

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress AbbVie has shared significant findings from the ECLIPSE study at the European Headache Congress, highlighting Atogepant's effectiveness in treating migraines.

AbbVie's ECLIPSE Study Revelations: Atogepant's Efficacy Against Migraine at European Headache Congress #USA #North_Chicago #Atogepant #ECLIPSE_Study #AQUIPTA

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma AbbVie has announced that their drug Epcoritamab in combination with rituximab and lenalidomide has received FDA approval for treating relapsed follicular lymphoma, showing significant results.

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma #United_States #Epcoritamab #North_Chicago #Rituximab #Lenalidomide

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie's Presentation of ECLIPSE Phase 3 Data Highlights Atogepant's Effectiveness for Migraine Relief AbbVie unveils Phase 3 ECLIPSE data at the European Headache Congress, showcasing Atogepant's superior efficacy over placebo for acute migraine treatment.

AbbVie's Presentation of ECLIPSE Phase 3 Data Highlights Atogepant's Effectiveness for Migraine Relief #USA #AbbVie #North_Chicago #Eclipse #Atogepant

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment AbbVie's Phase 3 ECLIPSE study reveals Atogepant's superiority to placebo in achieving pain freedom in acute migraine treatment, a significant advancement for patients.

AbbVie Announces Encouraging Phase 3 ECLIPSE Study Results for Atogepant in Migraine Treatment #United_States #AbbVie #North_Chicago #Atogepant #ECLIPSE_Study

Thiard News@F4F

@newsen.bsky.social

4 months ago

AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo AbbVie has announced successful Phase 3 trial results for Upadacitinib in treating Non-Segmental Vitiligo in adults and adolescents, marking a significant milestone.

AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo #United_States #AbbVie #North_Chicago #Upadacitinib #Non-Segmental_Vitiligo